The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success
PCI Pharma Services (PCI) is set to showcase its expertise in Phase I clinical trials in Australia with a series of West Coast US seminars to be held in January 2019.
During the last 20 years, Australia has become established as a preferred destination for the conduct of early phase clinical trials by virtue of significant economic advantages, speed-to-study advantages, as well as favourable regulatory pathways.
The proven excellence and performance of the country’s Clinical Trial institutions are supported by a highly favourable regulatory and business environment. The Australian Government’s commitment to the clinical trial sector is demonstrable, with significant incentives to help ensure success for early phase studies.
Within the Asia-Pacific region, Australia is now one of the more mature markets for conducting Clinical Trials, with more than $1 billion sector investment for research and development. Phase I clinical trial activity in Australia saw a 17.2% growth in 2012-2015, compared with just 1.8% globally.
The three West Coast seminars will be hosted by PCI in partnership with Nucleus Network and Prime Financial Group AU.
Nucleus Network is Australia’s industry leading contract research organisation specialising in the conduct of first-in-human, Phase I clinical trials. Prime Financial Group provides accounting and business advisory services, offering significant experience in R&D financing and incentives for life sciences companies.
At each of the three events, Cameron Johnson, Chief Executive Officer and Managing Director of Nucleus Network, will discuss "Phase I Clinical Trials in Australia," covering trial set-up and design to support applications and facilitate rapid approval.
During his presentation, Brendan Brown, Partner at Prime Accounting and Business Advisory Services, will explore "The Cost of your Trial in Australia." He will take a specific focus on eligibility requirements for Australia’s attractive R&D tax incentive programme.
PCI’s Craig Rogers, SVP Asia Pacific region, will provide an overview of the regulatory and investigational product management requirements for Phase I studies in Australia.
Craig will give up-to-date information on the regulatory framework, comparing Australian requirements with those of the EU and US markets. Craig will also set out the various options available for investigational product management, including importing, just in time manufacture and GMP requirements for Phase I labelling.
“Australia has established a significant presence in the global clinical trials sector during the past 20 years as a preferred destination for companies undertaking Phase I studies."
"This trend has been exemplified by the number of West Coast US pharma names which have identified the specific advantages of the region. PCI is delighted to partner with Nucelus Network and Prime for these seminars to share our respective experience and expertise,” commented Craig.